1
|
Guerra P, Ruvoletto M, Quarta S, Boninsegna G, Biasiolo A, Cagnin S, Angeli P, Pontisso P, Martini A. The impact of serpinB3-PD polymorphism on the prognosis of patients with hepatocellular carcinoma. Transl Oncol 2025; 57:102413. [PMID: 40367592 DOI: 10.1016/j.tranon.2025.102413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2024] [Revised: 04/17/2025] [Accepted: 05/10/2025] [Indexed: 05/16/2025] Open
Abstract
BACKGROUND HCC ranks as the third leading cause of cancer-related death, yet current surveillance strategies miss over one-third of cases at an early stage. SerpinB3-PD (SB3-PD), a polymorphic isoform of a serine-protease inhibitor involved in tumorigenesis and fibrogenesis, has been related to a more rapid cirrhosis decompensation. This study investigates the prognostic role of SB3-PD in patients with HCC. METHODS SB3-PD polymorphism was assessed in 140 patients with HCC, followed up in our outpatient Clinic. Cell invasion analysis was conducted on HepG2 cells either overexpressing the SB3 wild-type (HepG2/SB3WT) or the PD isoform (HepG2/SB3PD). The effect of recombinant SB3-WT or SB3-PD on the production of molecules that impair immunosurveillance was also assessed in the THP-1 monocytic cell line. RESULTS Patients carrying SB3-PD polymorphism showed worse tumour characteristics, associated with significantly lower survival and SB3-PD was an independent predictor of mortality. HepG2/SB3PD cells had a significantly higher invasion capacity than the HepG2/SB3WT. In THP-1 cells recombinant SB3-PD induced higher levels of PDL1 and IL-13 than SB3-WT. CONCLUSION SB3-PD isoform is associated with worse clinical prognosis in patients with HCC. These findings were supported in vitro by increased cellular invasion and higher production of molecules impairing immunosurveillance.
Collapse
Affiliation(s)
- Pietro Guerra
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy
| | - Mariagrazia Ruvoletto
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy; European Reference Network - ERN RARELIVER, Department of Medicine, Azienda Ospedale-Università, Padova, Italy
| | - Santina Quarta
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy; European Reference Network - ERN RARELIVER, Department of Medicine, Azienda Ospedale-Università, Padova, Italy
| | - Giulia Boninsegna
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy
| | - Alessandra Biasiolo
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy; European Reference Network - ERN RARELIVER, Department of Medicine, Azienda Ospedale-Università, Padova, Italy
| | - Silvia Cagnin
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy
| | - Paolo Angeli
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy; European Reference Network - ERN RARELIVER, Department of Medicine, Azienda Ospedale-Università, Padova, Italy
| | - Patrizia Pontisso
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy; European Reference Network - ERN RARELIVER, Department of Medicine, Azienda Ospedale-Università, Padova, Italy
| | - Andrea Martini
- Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, via Giustiniani, 2, 35128, Padova, Italy; European Reference Network - ERN RARELIVER, Department of Medicine, Azienda Ospedale-Università, Padova, Italy.
| |
Collapse
|
2
|
Cagnin S, Pontisso P, Martini A. SerpinB3: A Multifaceted Player in Health and Disease-Review and Future Perspectives. Cancers (Basel) 2024; 16:2579. [PMID: 39061218 PMCID: PMC11274807 DOI: 10.3390/cancers16142579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Revised: 07/10/2024] [Accepted: 07/16/2024] [Indexed: 07/28/2024] Open
Abstract
SerpinB3, a member of the serine-protease inhibitor family, has emerged as a crucial player in various physiological and pathological processes. Initially identified as an oncogenic factor in squamous cell carcinomas, SerpinB3's intricate involvement extends from fibrosis progression and cancer to cell protection in acute oxidative stress conditions. This review explores the multifaceted roles of SerpinB3, focusing on its implications in fibrosis, metabolic syndrome, carcinogenesis and immune system impairment. Furthermore, its involvement in tissue protection from oxidative stress and wound healing underscores its potential as diagnostic and therapeutic tool. Recent studies have described the therapeutic potential of targeting SerpinB3 through its upstream regulators, offering novel strategies for cancer treatment development. Overall, this review underscores the importance of further research to fully elucidate the mechanisms of action of SerpinB3 and to exploit its therapeutic potential across various medical conditions.
Collapse
Affiliation(s)
| | - Patrizia Pontisso
- Department of Medicine, University of Padova, 35123 Padova, Italy; (S.C.); (A.M.)
| | | |
Collapse
|
3
|
Jing H, Lin L, Xu J, Zhang H, Cao L, Fan Y. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis-More evidence needed. Aliment Pharmacol Ther 2024; 59:911-912. [PMID: 38462691 DOI: 10.1111/apt.17901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 01/28/2024] [Indexed: 03/12/2024]
Abstract
LINKED CONTENTThis article is linked to Martini et al papers. To view these articles, visit https://doi.org/10.1111/apt.17804 and https://doi.org/10.1111/apt.17916
Collapse
Affiliation(s)
- Haibo Jing
- Department of General Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
| | - Lin Lin
- Department of Gastroenterology, Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China
| | - Juan Xu
- Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
| | - Huifeng Zhang
- Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
| | - Lin Cao
- Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
| | - Yaofu Fan
- Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
| |
Collapse
|
4
|
Martini A, Pontisso P. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis-More evidence needed. Authors' reply. Aliment Pharmacol Ther 2024; 59:913-914. [PMID: 38462679 DOI: 10.1111/apt.17916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
LINKED CONTENTThis article is linked to Martini et al papers. To view these articles, visit https://doi.org/10.1111/apt.17804 and https://doi.org/10.1111/apt.17901
Collapse
Affiliation(s)
- Andrea Martini
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| | - Patrizia Pontisso
- Unit of Internal Medicine and Hepatology, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
- European Reference Network - ERN RARE-LIVER, Department of Medicine, Azienda Ospedaliera-Università, Padova, Italy
| |
Collapse
|